Sam Brusco, Associate Editor01.12.24
SimBioSys has appointed esteemed breast surgical oncologist Dr. Barry Rosen as its new chief medical officer.
Dr. Rosen has over 25 years of clinical experience, serving on the faculty at the American Society of Breast Surgeons (ASBrS), the School of Oncoplastic Surgery and the National Consortium of Breast Centers. He is also chairman of the NQMBC (National Quality Metrics for Breast Centers) and participation in the Patient Safety and Quality Committee for the ASBrS.
The company said the move coincides with the announcement of U.S. Food and Drug Administration (FDA) clearance for its TumorSight digital medicine platform earlier this month. TumorSight Viz uses artificial intelligence (AI) to automatically segment tumors and surrounding tissue to display a 3D visualization. It also provides tumor volume, tumor-to-breast volume, and tumor distance to key anatomical structures in the breast.
For the past year, Dr. Rosen has also clinically advised SimBioSys. He compared the TumorSight plan’s approach to undergoing a home remodeling project.
"Instead of immediately starting the remodel, the best contractors with the right tools can give you a 3D model of your current home and walk you through the best option for the remodel and explain why certain things are possible or not,” he explained. “These tools not only help contractors determine what is possible and optimal, but they serve as an important educational tool that helps homeowners understand more clearly, make a more informed decision and feel much more confident in that decision.”
“His addition comes at a crucial juncture as we bring TumorSight to market, expand our clinical portfolio and advance our groundbreaking research product, PhenoScope,” said SimBioSys CEO Tushar Pandey. “Barry's extensive expertise as a practicing oncologist will play a key role in advancing our technologies to gain new insights into tumor biology and address real-world challenges in the cancer community."
Dr. Rosen has over 25 years of clinical experience, serving on the faculty at the American Society of Breast Surgeons (ASBrS), the School of Oncoplastic Surgery and the National Consortium of Breast Centers. He is also chairman of the NQMBC (National Quality Metrics for Breast Centers) and participation in the Patient Safety and Quality Committee for the ASBrS.
The company said the move coincides with the announcement of U.S. Food and Drug Administration (FDA) clearance for its TumorSight digital medicine platform earlier this month. TumorSight Viz uses artificial intelligence (AI) to automatically segment tumors and surrounding tissue to display a 3D visualization. It also provides tumor volume, tumor-to-breast volume, and tumor distance to key anatomical structures in the breast.
For the past year, Dr. Rosen has also clinically advised SimBioSys. He compared the TumorSight plan’s approach to undergoing a home remodeling project.
"Instead of immediately starting the remodel, the best contractors with the right tools can give you a 3D model of your current home and walk you through the best option for the remodel and explain why certain things are possible or not,” he explained. “These tools not only help contractors determine what is possible and optimal, but they serve as an important educational tool that helps homeowners understand more clearly, make a more informed decision and feel much more confident in that decision.”
“His addition comes at a crucial juncture as we bring TumorSight to market, expand our clinical portfolio and advance our groundbreaking research product, PhenoScope,” said SimBioSys CEO Tushar Pandey. “Barry's extensive expertise as a practicing oncologist will play a key role in advancing our technologies to gain new insights into tumor biology and address real-world challenges in the cancer community."